Response Oncology, Inc. (ROIX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Response Oncology, Inc. (ROIX) trades at $0.00 with AI Score 46/100 (Grade C). Response Oncology, Inc. is a company that formerly operated as a comprehensive cancer management company. Market cap: $12, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for ROIX: ROIX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ROIX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ROIX: the 1 perspectives are evenly split.
How is this calculated? →Response Oncology, Inc. (ROIX) Healthcare & Pipeline Overview
Response Oncology, Inc., incorporated in 1984, previously offered advanced cancer treatment services, managed oncology practices, and compounded pharmaceuticals. Following the liquidation of its operating assets in 2002, the company has ceased significant operations and is based in Memphis, Tennessee.
What Is the Investment Thesis for ROIX?
Response Oncology, Inc. presents a unique case for investors, given its historical context and current state. The company liquidated its operating assets in 2002 and has no significant operations as of 2026. With a market capitalization of 12 and a beta of -19.14, the stock's behavior may not align with typical market dynamics. Potential investors should carefully consider the implications of the company's dormant operational status and the absence of revenue-generating activities. Any investment decision should be based on a thorough understanding of the company's historical filings and any potential future plans, if disclosed.
Based on FMP financials and quantitative analysis
ROIX Key Highlights
- Market Cap: $0.00B indicates the company has negligible market capitalization.
- Beta: -19.14 suggests the stock price moves inversely to the market, but this may not be reliable given the lack of operations.
- Liquidation of assets completed in 2002, marking a significant shift in the company's business model.
- No significant operations as of 2026, indicating a dormant business state.
- Employee count of 10 suggests minimal ongoing business activity.
Who Are ROIX's Competitors?
ROIX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| HWAIF Healwell AI Inc. | $0.53 | -3.52% | $160.75M | 65 |
| ASSF Assisted 4 Living, Inc. | $1.00 | +0.00% | $45.35M | 63 |
| FTRP Field Trip Health Ltd. | $0.84 | +1.07% | $9.81M | 62 |
| SLHGP Skylight Health Group Inc. | $12.00 | -5.88% | 61 | |
| NWKHY Netcare Limited | $7.17 | +0.00% | $843.64M | 50 |
| AONC American Oncology Network, Inc. | $10.00 | +0.00% | $292.48M | 50 |
| DCGO DocGo Inc. | $0.59 | +5.81% | $58.07M | 51 |
| JYNT The Joint Corp. | $9.16 | +2.10% | $130.55M | 51 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ROIX's Key Strengths?
- Historical presence in cancer management.
- Established network of IMPACT Centers (prior to liquidation).
- Experience in pharmaceutical compounding.
- Conducted outcomes research.
What Are ROIX's Weaknesses?
- No significant operations as of 2026.
- Liquidated substantially all operating assets in 2002.
- Lack of current revenue streams.
- Limited market presence.
What Could Drive ROIX Stock Higher?
- Potential for restructuring or acquisition by another company.
- Any future announcements regarding the company's plans or operations.
- Changes in the regulatory environment that could impact the company's prospects.
What Are the Key Risks for ROIX?
- Lack of liquidity in the OTC market.
- Limited or no financial disclosure.
- High price volatility.
- The company has no significant operations.
- Uncertainty regarding the company's future plans.
What Are the Growth Opportunities for ROIX?
- Growth opportunity 1: Given that Response Oncology, Inc. has liquidated its operating assets and has no significant operations, traditional growth opportunities are not applicable. Any potential future growth would depend on a complete restructuring and a new business plan, which is not currently evident. The company would need to identify a new market, develop a viable business model, and secure funding to pursue any growth initiatives. This would essentially be a new venture under the same corporate shell.
- Growth opportunity 2: The company could explore opportunities in healthcare technology, leveraging any remaining intellectual property or expertise from its past operations. This would require significant investment in research and development, as well as a deep understanding of current market needs and technological trends. The market for healthcare technology is projected to reach $280 billion by 2028, presenting a substantial opportunity for a company with the right strategy and resources.
- Growth opportunity 3: Response Oncology could potentially re-enter the oncology care market by focusing on niche areas such as personalized medicine or telemedicine. This would require a strategic shift towards innovation and a focus on delivering specialized services to a targeted patient population. The personalized medicine market is expected to grow to $4.2 billion by 2027, offering a potential avenue for growth.
- Growth opportunity 4: The company could consider acquiring or merging with another healthcare company to gain access to new markets, technologies, or expertise. This would require careful due diligence and a clear understanding of the strategic fit between the two organizations. The healthcare industry is undergoing consolidation, with numerous mergers and acquisitions occurring each year, presenting opportunities for companies to expand their reach and capabilities.
- Growth opportunity 5: Response Oncology could explore opportunities in the development of new cancer therapies or diagnostic tools. This would require significant investment in research and development, as well as a strong understanding of the regulatory landscape and the clinical trial process. The market for cancer therapies is projected to reach $200 billion by 2027, offering a substantial opportunity for companies that can develop innovative treatments.
What Opportunities Does ROIX Have?
- Potential for restructuring and re-entry into the healthcare market.
- Leveraging historical expertise in oncology care.
- Exploring opportunities in healthcare technology.
- Acquiring or merging with another healthcare company.
What Threats Does ROIX Face?
- Competition from established healthcare providers.
- Evolving regulatory landscape in the healthcare industry.
- Difficulty in securing funding for new ventures.
- Risk of obsolescence due to technological advancements.
What Are ROIX's Competitive Advantages?
- Historically, the company's network of IMPACT Centers provided a degree of geographic advantage.
- Relationships with practicing oncologists offered a competitive edge in patient referrals.
- In-house pharmaceutical compounding provided cost control and supply chain advantages.
- Outcomes research capabilities differentiated the company in the pharmaceutical market.
What Does ROIX Do?
Response Oncology, Inc., established in 1984 and based in Memphis, Tennessee, once operated as a comprehensive cancer management company. The company, along with its subsidiaries, provided advanced cancer treatment services through outpatient facilities known as IMPACT Centers, under the direction of practicing oncologists. Additionally, Response Oncology owned the assets of and managed the non-medical aspects of oncology practices. The company also compounded and dispensed pharmaceuticals to certain oncologists for a fixed or cost-plus fee. Furthermore, Response Oncology conducted outcomes research on behalf of pharmaceutical manufacturers. However, as of May 20, 2002, the company liquidated substantially all of its operating assets. It anticipated that the remaining assets would be liquidated and all wind-down activities completed by the end of 2002, effectively ceasing its primary business operations. Currently, Response Oncology, Inc. does not have significant operations.
What Products and Services Does ROIX Offer?
- Formerly provided advanced cancer treatment services through outpatient facilities.
- Managed the non-medical aspects of oncology practices.
- Compounded and dispensed pharmaceuticals to oncologists.
- Conducted outcomes research for pharmaceutical manufacturers.
- Operated IMPACT Centers under the direction of practicing oncologists.
- Liquidated substantially all operating assets as of May 20, 2002.
- Currently has no significant operations.
How Does ROIX Make Money?
- Historically, Response Oncology generated revenue through cancer treatment services.
- Revenue was also derived from managing oncology practices.
- Pharmaceutical compounding and dispensing contributed to revenue streams.
- Outcomes research conducted for pharmaceutical manufacturers provided additional income.
What Industry Does ROIX Operate In?
Response Oncology, Inc. formerly operated within the medical care facilities industry, which involves providing services such as cancer treatment through outpatient facilities. The industry is characterized by technological advancements in treatment methods, evolving regulatory landscapes, and a focus on patient care. However, given that Response Oncology liquidated its assets in 2002, its current relevance to the industry is limited. Competitors in this space include companies like GNRS, LHRP, QMED, RFCS, and SYNI, which continue to operate and innovate within the healthcare sector.
Who Are ROIX's Key Customers?
- Practicing oncologists who directed IMPACT Centers.
- Patients receiving cancer treatment services.
- Pharmaceutical manufacturers seeking outcomes research.
- Oncology practices for which Response Oncology managed non-medical aspects.
Response Oncology, Inc. (ROIX) Valuation Context
Relative to its peer group, ROIX's quantitative score of 46/100 is below the peer average of 60/100.
ROIX Financials
Bull Case vs Bear Case
Bull Case
- Historical presence in cancer management.
- Established network of IMPACT Centers (prior to liquidation).
- Experience in pharmaceutical compounding.
- Conducted outcomes research.
Bear Case
- No significant operations as of 2026.
- Liquidated substantially all operating assets in 2002.
- Lack of current revenue streams.
- Limited market presence.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
ROIX Latest News
No recent news available for ROIX.
ROIX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ROIX.
Price Targets
Wall Street price target analysis for ROIX.
ROIX MoonshotScore
What does this score mean?
The MoonshotScore rates ROIX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Charles E. Sweet
Managing Employee
Charles E. Sweet currently manages 10 employees at Response Oncology, Inc. Information regarding his detailed career history, education, and previous roles is not available in the provided data. Further research would be required to ascertain his specific qualifications and experience in the healthcare industry or related fields. His role involves overseeing the remaining operations of the company following the liquidation of its assets.
Track Record: Due to the limited information available, it is difficult to assess Charles E. Sweet's track record at Response Oncology, Inc. The company liquidated its operating assets in 2002, and his role appears to be primarily focused on managing the remaining wind-down activities. Specific achievements or strategic decisions under his leadership cannot be determined based on the provided data.
ROIX OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, encompassing securities that are not eligible for quotation on OTCQX or OTCQB. These securities often include those of distressed companies, shell companies, and companies with limited or no public information. Companies on the OTC Other tier may not meet minimum financial standards or have chosen not to comply with OTCQX or OTCQB requirements. Investing in securities on this tier carries a higher degree of risk due to the lack of regulatory oversight and transparency compared to securities listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited or no financial disclosure.
- Potential for fraud or manipulation.
- Lack of regulatory oversight.
- High price volatility.
- Illiquidity and difficulty in trading shares.
- Verify the company's legal status and registration.
- Attempt to obtain any available financial statements.
- Assess the company's management team and their experience.
- Research any legal or regulatory issues involving the company.
- Understand the company's business model and its prospects.
- Evaluate the liquidity of the stock and the potential for trading difficulties.
- Check for any available public filings or disclosures.
- Verify the company's contact information and physical address.
- Assess the company's website and online presence.
- Look for any independent audits or certifications.
- Research the background of the company's management team.
ROIX Healthcare Stock FAQ
What does Response Oncology, Inc. do?
Response Oncology, Inc. formerly operated as a comprehensive cancer management company, providing advanced cancer treatment services, managing oncology practices, and compounding pharmaceuticals. However, the company liquidated substantially all of its operating assets in 2002 and currently has no significant operations. Any future business activities would depend on a complete restructuring and a new business plan.
What do analysts say about ROIX stock?
There is no current analyst coverage for ROIX stock due to the company's lack of significant operations and its listing on the OTC Other tier. The stock's behavior may not align with typical market dynamics, and traditional valuation metrics may not be applicable. Potential investors should conduct their own due diligence and carefully consider the risks associated with investing in this stock.
What are the main risks for ROIX?
The main risks for ROIX include the company's lack of significant operations, limited or no financial disclosure, high price volatility, and illiquidity in the OTC market. There is also uncertainty regarding the company's future plans and the potential for fraud or manipulation. Investors should be aware of these risks and conduct thorough due diligence before considering an investment in ROIX.
What are the key factors to evaluate for ROIX?
Response Oncology, Inc. (ROIX) holds an AI score of 46/100 (low). Not financial advice.
How frequently does ROIX data refresh on this page?
ROIX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ROIX's recent stock price performance?
Response Oncology, Inc. (ROIX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Historical presence in cancer management. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ROIX overvalued or undervalued right now?
Valuing Response Oncology, Inc. (ROIX) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ROIX?
Before investing in Response Oncology, Inc. (ROIX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may not be complete.
- The company's financial and operational status may have changed since the last available information.
- OTC market investments carry significant risks.